Related Experiment Video
Updated: May 6, 2026
10:47
Immuno-fluorescence Assay of Leptospiral Surface-exposed Proteins
Published on: July 1, 2011
15.7K
ErpY-LemA: A breakthrough in human leptospirosis diagnosis
Thayná Laner Cardoso1, Isabel Ladeira Pereira1, Daniela Rodriguero Wozeak1
1Laboratory of Bacteriology and Bioassays, Department of Microbiology and Parasitology, Institute of Biology, Federal University of Pelotas, Pelotas, RS, Brazil.
Diagnostic Microbiology and Infectious Disease
|May 21, 2025
Summary
A new diagnostic tool for leptospirosis (a bacterial disease) shows promise. The ErpY-LemA chimera antigen accurately detects both IgM and IgG antibodies, offering a sensitive and specific method for diagnosing leptospirosis.
Area of Science:
- Medical Microbiology
- Immunodiagnostics
- Infectious Diseases
Background:
- Leptospirosis is a global public health issue, especially in tropical areas.
- Current diagnostic methods for leptospirosis face challenges due to nonspecific symptoms and limitations.
- There is a need for improved diagnostic tools for leptospirosis.
Purpose of the Study:
- To evaluate the diagnostic potential of a novel recombinant chimera, ErpY-LemA, for diagnosing human leptospirosis.
- To assess the sensitivity and specificity of ErpY-LemA based enzyme-linked immunosorbent assays (ELISAs) for detecting IgM and IgG antibodies.
- To determine if the ErpY-LemA chimera can provide non-serovar-specific detection of Leptospira infection.
Main Methods:
- The recombinant chimera ErpY-LemA was constructed and expressed in Escherichia coli.
- Antigenicity of the chimera was tested against sera from infected hamsters.
- ELISA assays were performed using 80 human sera previously characterized by microscopic agglutination test (MAT), assessing both acute and convalescent phases, as well as unknown disease stages.
Main Results:
- The ErpY-LemA chimera demonstrated strong antigenicity and recognized sera from diverse Leptospira serovars, indicating non-serovar-specific reactivity.
- IgM detection in the acute phase showed 95% sensitivity and specificity (AUC = 0.990).
- IgG detection in the convalescent phase showed 80% sensitivity and 100% specificity (AUC = 0.968).
- ELISAs using ErpY-LemA maintained high diagnostic performance (≥95% sensitivity and specificity, AUC > 0.98) regardless of the disease stage.
Conclusions:
- The ErpY-LemA chimera is a highly promising antigen for developing a rapid and cost-effective serological diagnostic test for human leptospirosis.
- The diagnostic test exhibits high sensitivity and specificity, irrespective of the infecting Leptospira serovar or disease stage.
- This novel diagnostic approach could significantly improve the management of leptospirosis worldwide.
